While analyzing the DNA methylome of multiple myeloma (MM), a plasma cell neoplasm, by whole-genome bisulfite sequencing and high-density arrays, we observed a highly heterogeneous pattern globally characterized by regional DNA hypermethylation embedded in extensive hypomethylation. In contrast to the widely reported DNA hypermethylation of promoter-associated CpG islands (CGIs) in cancer, hypermethylated sites in MM, as opposed to normal plasma cells, were located outside CpG islands and were unexpectedly associated with intronic enhancer regions defined in normal B cells and plasma cells. Both RNA-seq and in vitro reporter assays indicated that enhancer hypermethylation is globally associated with down-regulation of its host genes. ChIP-seq and DNase-seq further revealed that DNA hypermethylation in these regions is related to enhancer decommissioning. Hypermethylated enhancer regions overlapped with binding sites of B cellspecific transcription factors (TFs) and the degree of enhancer methylation inversely correlated with expression levels of these TFs in MM. Furthermore, hypermethylated regions in MM were methylated in stem cells and gradually became demethylated during normal B-cell differentiation, suggesting that MM cells either reacquire epigenetic features of undifferentiated cells or maintain an epigenetic signature of a putative myeloma stem cell progenitor. Overall, we have identified DNA hypermethylation of developmentally regulated enhancers as a new type of epigenetic modification associated with the pathogenesis of MM.
Multiple myeloma (MM) is an aggressive and incurable neoplasm characterized by clonal proliferation of plasma cells in the bone marrow and a marked clinico-biological heterogeneity (Morgan et al. 2012; Bergsagel et al. 2013) . MM frequently arises from a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS) , although the precise molecular mechanisms involved in the progression from MGUS to MM are only partially understood. Various distinct genetic abnormalities have been observed in both MM and MGUS, including gene mutations, chromosomal rearrangements, or aneusomies (Bergsagel and Kuehl 2005; Chng et al. 2006; Chapman et al. 2011) .
Besides genetic abnormalities, recent studies have shown that epigenetic changes such as DNA methylation play an important role in MM. Various reports indicate that DNA methylation patterns are capable of distinguishing normal plasma cells (NPCs) from MGUS and MM cells. The major differences between these entities can be explained by the occurrence of DNA hypomethylation in malignant plasma cells (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013) . In addition to this DNA hypomethylation, some studies have demonstrated aberrant DNA hypermethylation of promoter regions of different tumor suppressor genes in MM, although the classical CpG island methylator phenotype (CIMP) extensively observed in a wide variety of tumors (Issa 2004 ) has been rarely reported in MM (Martin et al. 2008 ). Hypermethylation of RASD1, for example, has been correlated with resistance of MM to dexamethasone (Nojima et al. 2009 ). Inappropriate DNA methylation of TNFRSF18 (also known as GITR) (Liu et al. 2013) , MIR34B/C (Wong et al. 2011) , or the combined inactivation of genes GPX3, RBP1, SPARC, and TGFBI (Kaiser et al. 2013 ) have been associated with poor prognosis, survival, and disease progression in patients with MM.
In spite of these significant findings, the high-throughput DNA methylation reports published so far in MM were restricted to the study of promoter regions (Nojima et al. 2009; Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013; Kaiser et al. 2013) . Hence, the purpose of our study was to adopt a more extensive and unbiased analysis of the DNA methylome, including promoters, gene bodies, and intergenic regions in normal plasma cells (NPC) and plasma cells from MGUS and MM patient samples. Using this approach, we have identified that DNA methylation of B cell-specific enhancer regions is a new phenomenon associated with MM pathogenesis.
Results
The DNA methylome of MM is globally characterized by a large degree of heterogeneity To analyze the DNA methylome and define general epigenetic signatures associated with plasma cell disorders, we applied the HumanMethylation450 BeadChip (Illumina) to purified plasma cells obtained from bone marrow samples of MM (n = 104) and MGUS (n = 16) patients as well as normal bone marrows (n = 3 pools from four donors each) and nontumoral tonsils (n = 8) (Supplemental Table 1 ). Unsupervised principal component analysis of the normalized DNA methylation data identified a clear distinction between NPC and MM samples, with a larger degree of heterogeneity in the myeloma plasma cells (Fig. 1A,B ; Supplemental Fig. 1 ). Next, we further characterized this heterogeneity of MM by comparing it with other lymphoid malignancies. We calculated the median methylation value per case and measured the variability per entity. The coefficient of variation (CV) was significantly higher (P < 0.001) in MM (CV = 30.7) than in acute lymphoblastic leukemia (ALL; CV = 7.9), chronic lymphocytic leukemia (CLL; CV = 5.3), and diffuse large B cell lymphoma (DLBCL; CV = 10.4) (Fig. 1C ). This analysis shows that the extreme heterogeneity of DNA methylation levels seems to be an epigenetic feature that is specific for MM. To further characterize this variable pattern, we sequenced the whole DNA methylome at a single base pair resolution (>51-fold coverage per sample) of NPCs from bone marrow and two MMs in which the HumanMethylation450 BeadChip indicated extreme hyper-or hypomethylation (white arrows in Fig.  1B ; Supplemental Tables 1, 2; Supplemental Fig. 1 ). Indeed, these analyses validated the array data at the whole-genome level, with the genome of MM1 being hypermethylated and that of MM2 being hypomethylated as compared to NPCs (Fig. 1D-F) . Hence, MM can show different methylomes, with a wide range of methylation levels that range from globally hypo-to hypermethylated.
Detection of aberrant DNA methylation in MM and MGUS
To obtain a reliable whole-genome measure of the magnitude of epigenetic changes in MM, we compared the methylation levels of each MM sample with extreme methylation patterns and NPCs. Sample MM1 showed 1,504,700 differentially methylated regions (DMRs) covering a total of 2,158,824 CpG dinucleotides, whereas MM2 had 1,875,824 DMRs covering 4,308,958 CpGs. As previously suggested in Figure 1D , the majority of DMRs identified in MM2 were hypomethylated, whereas MM1 showed less hypomethylation and increased hypermethylation levels ( Fig. 2A,B) .
Next, we attempted to generate a consensus differential methylation signature of MGUS and MM in comparison with NPCs, using microarray data of a large series of samples ( Fig. 2C-E) . From 78,998 differentially methylated CpGs identified between MM and NPC, the great majority were hypomethylated (98.3%). In MGUS, we detected 9388 differentially methylated CpGs, of which 6874 (73.2%) were hypomethylated and 2514 (26.8%) hypermethylated ( Fig. 2C-E; Supplemental Fig. 2) . A direct comparison between MM and MGUS revealed that the progression from MGUS to MM seems to be associated with increased hypomethylation in the absence of additional hypermethylation events (Supplemental Fig. 3) .
Applying an unsupervised analysis in order to compare the DNA methylation profiles of clinically relevant MM subtypes based on the presence or absence of cytogenetic alterations, i.e., hyperdiploidy, chromosomal translocations affecting the immunoglobulin heavy chain (IGH) locus and TP53 deletions, we did not find any apparent association ( Fig. 1B; Supplemental Fig. 4) . These results were confirmed using a supervised approach, in which we observed only a few differentially methylated CpGs between cytogenetic subgroups (Supplemental Fig. 5 ). However, these findings do not rule out the possibility that other genetic aberrations, not analyzed in our study, may be related to DNA methylation changes, as shown previously in MM as well as in other tumors (Weisenberger et al. 2006; Walker et al. 2011 ).
Hypo-and hypermethylated CpGs in MM are located in specific genomic regions and enriched in particular chromatin states Hypomethylated sites in MM and MGUS mainly occurred in regions lacking CpG islands (CGI) and were predominantly located in gene bodies and intergenic regions. Although both whole-genome bisulfite sequencing (WGBS) and HumanMethylation450 BeadChip showed this effect, the enrichment, when compared with the background distribution, was particularly evident in the consensus signature (MM versus NPCs) derived from HumanMethylation450 BeadChip. Interestingly, hypermethylated sites also occurred in regions lacking CGIs (Supplemental Fig. 6 ). In order to investigate the functional significance of aberrant DNA methylation in MM, we annotated hypo-and hypermethylated CpGs according to functional chromatin states recently described by ChIP-seq in immortalized mature B cells (IMBCs) (Ernst et al. 2011) , which have a DNA methylation profile similar to normal memory B cells and plasma cells (Supplemental Fig. 7 ). As previously observed in colon cancer (Berman et al. 2011) , the great majority (75%-80%) of hypomethylated CpGs in MM and MGUS, or those losing methylation in the progression from MGUS to MM, were located in heterochromatic and late-replicating regions such as lamina-associated domains (LADs) (Fig. 2F; Supplemental Figs. 3, 8) . We analyzed the potential effect of this epigenetic change and we found neither a morphological alteration of the chromatin bound to the nuclear lamina by electron microscopy nor a detachment of hypomethylated regions from the nuclear lamina by 3D-FISH. We then studied the transcriptome of 11 MM cases and four NPCs by RNA-seq, and we observed that genes located in hypomethylated heterochromatic regions globally showed low expression levels both in NPCs and MMs regardless of their methylation status (Supplemental Fig. 9 ). Furthermore, focusing only on promoter regions undergoing demethylation, only 1.9% of the CpGs showed a significant correlation (P < 0.01) with gene expression. These data suggest that heterochromatin hypomethylation seems to have a low impact on gene expression.
Remarkably, a large proportion of hypermethylated CpGs in MM (n = 794; 59.9%; P < 1 × 10 −12 ) (Supplemental Table 3 ) and MGUS (n = 1656; 65.9%; P < 1 × 10
) were located within enhancer regions (Figs. 2F, 3A; Supplemental Fig. 10 ), and in particular, within intronic enhancers (Supplemental Fig. 11 ). To evaluate whether differential methylation of enhancers in MM may be functionally relevant, we analyzed the expression of their associated genes by RNA-seq. Overall, we observed a shift toward an inverse correlation between enhancer methylation and their associated gene expression as compared to nonenhancer intronic regions of the same genes ( Fig. 3B-F ; Supplemental Table 4), which mostly took place in the absence of DNA methylation changes in the corresponding promoter regions (Supplemental Fig. 12 ). In fact, of the 50 genes with the strongest inverse correlation between enhancer methylation and gene expression, only two (4%) showed concurrent promoter hypermethylation. We further analyzed the consequences of differential DNA methylation at enhancer regions and observed that treating a MM cell line with 5-azacytidine led to increased expression of SLC15A4 and PVT1 (Supplemental Fig. 13 ). Due to the unspecificity of this pharmacological treatment, we also performed reporter assays using a CpGFree Luciferase Vector (Klug and Rehli 2006) . We cloned three enhancer regions into this vector, which showed variable levels of correlation between DNA methylation and expression levels (Supplemental Table 5 ). Luciferase activity analyzed in transient transfection assays comparing unmethylated and in vitro methylated vectors revealed that upon enhancer methylation, the luciferase activity was reduced, further supporting our findings in primary tumors (Fig. 3D-F) .
Hypermethylation of B cell-specific enhancers in MM is associated with enhancer decommissioning
After showing that DNA methylation is related to enhancer activity, we attempted to analyze the biological function of the genes Table 6 ). Furthermore, using transcription factor binding sites (TFBSs) identified by ChIP-seq in the ENCODE Project (Gerstein et al. 2012) , we observed that hypermethylated enhancers overlapped with binding sites of transcription factors (TFs) associated with B-cell differentiation such as BCL11A, BATF, EBF1, and PAX5 (Supplemental Table 7 ). These data led us to investigate whether the DNA methylation levels of these enhancer regions are modulated during normal B-cell differentiation. We analyzed the DNA methylation profiles of seven B-cell differentiation stages, including hematopoietic multipotent progenitors, several immature B cells, naive B cells, germinal center B cells, and plasma cells. In addition, we included embryonic stem cells (ESCs) and IMBCs (Ernst et al. 2011 ) in the analysis, as well as other B-cell neoplasms such as CLL (n = 139) (Kulis et al. 2012) , ALL (n = 46) (Busche et al. 2013), and DLBCL (n = 40) . Surprisingly, the 794 enhancer-associated CpGs hypermethylated in MM were also methylated in ESCs and gradually lost DNA methylation, finally becoming completely unmethylated in germinal center B cells and terminally differentiated plasma cells (Fig. 4A) . We found that ALLs appear to maintain a methylation pattern resembling their cellular origin (precursor B cell), whereas DLBCLs, similarly to MM, show hypermethylation of B cell-specific enhancers when compared to their cell of origin (i.e., germinal center B cells) (Supplemental Fig. 14) .
Next, we studied whether enhancer hypermethylation in MM was accompanied by a change in the chromatin state. We performed ChIP-seq with antibodies against monomethylated lysine 4 (H3K4me1) and acetylated lysine 27 (H3K27ac) of histone H3 in NPCs and in the MM cell line U266, and also DNase-seq in the latter. Data were compared to ESCs (showing hypermethylated enhancers, similar to MM) and IMBCs (with unmethylated enhancers, similar to NPCs). As shown in Figure 4B , the genomic areas surrounding unmethylated enhancers in IMBCs show a clear enrichment of H3K4me1 and H3K27ac as well as DNase hypersensitive sites. In NPCs, the regions under study lost H3K27ac, but H3K4me1 showed a strong signal, indicating that they maintain their enhancer status. In contrast, methylated enhancers in ESCs and the U266 cell line actually represent decommissioned enhancers (Whyte et al. 2012; Rivera and Ren 2013) lacking all the 
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Cold Spring Harbor Laboratory Press on November 7, 2016 -Published by genome.cshlp.org Downloaded from enhancer-associated features (Fig. 4B,C) . Interestingly, 125 of the 794 enhancers with significant hypermethylation in MM cases were unmethylated in the U266 MM cell line. Similarly to IMBCs, these unmethylated B-cell enhancers were accompanied by a chromatin structure linked to active enhancers in the MM cell line (Fig. 4C ). This finding is further supported by the fact that enhancers (defined as such in IMBCs) hypomethylated in IMBCs, NPCs, and the MM cell line, but hypermethylated in ESCs, only showed active enhancer-related chromatin marks in the first three (Supplemental Fig. 15 ).
Down-regulation of B cell-specific transcription factors in MM is associated with enhancer hypermethylation
All the preceding results suggest that MMs acquire hypermethylation in enhancer regions that paradoxically undergo demethylation during normal B-cell differentiation (Fig. 4A) . Since the process of B-cell differentiation is guided by expression of stagespecific TFs (Matthias and Rolink 2005; Kurosaki et al. 2010) , the binding of TFs to their target enhancers may result in demethylation. Several lines of evidence support this model in which DNA demethylation during cell development is mediated by the presence of TFs, whose binding may block DNA methylation maintenance after cell division (Stadler et al. 2011; Lee et al. 2012; Feldmann et al. 2013; Hon et al. 2013; Kulis et al. 2013) . Interestingly, here we have observed the reverse process in plasma cell disorders in which B cell-specific TF binding sites seem to reacquire a chromatin state that is typical of undifferentiated cells. Therefore, we postulate that down-regulation of B cell-specific TFs in MM cells could result in enhancer methylation and decommissioning. To test this hypothesis, we analyzed the expression levels of B cell-specific TFs in MMs and NPCs by RNAseq and correlated them with the mean DNA methylation level of the enhancers with altered methylation in MM. Interestingly, for most of the B cell-specific TFs, we observed an inverse correlation between their expression and methylation levels of their target enhancers (Fig. 5A ). Among these, the expression of STAT5, PAX5, NFATC1, and BATF showed a significant negative correlation with DNA methylation levels of enhancers in normal and neoplastic plasma cells (Pearson coefficient ranging from −0.79 to −0.62, P < 0.05) ( Fig. 5A-D ; Supplemental Table 8) . Furthermore, variable expression of several of these TFs was coordinated in MM patients (Fig. 5E ), suggesting that the expression level of a TF network, and not that of individual TFs, was associated with the methylation levels of enhancers. In line with this finding, the expression levels of genes regulated by enhancer methylation also showed a correlated expression among MM patients (Supplemental Fig. 16 ). 
Discussion
In this study, we have characterized the DNA methylome of normal and neoplastic plasma cells using a double approach. On the one hand, we generated an epigenetic signature of common DNA methylation changes in MGUS and MM by comparing them to NPCs, using the HumanMethylation450 BeadChip in a large series of patients. On the other hand, we analyzed the whole DNA methylome at single base-pair resolution of two samples from the extremes of the DNA methylation spectrum of MM. This second approach allowed us to characterize the epigenetic heterogeneity in MM, to define the boundaries of DMRs, and to measure the magnitude of DNA methylation changes in MM at the whole-genome level.
As shown in other studies (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013 ), we describe a clear distinction in DNA methylation patterns between malignant and normal plasma cells, mostly in the form of hypomethylation in the former. Interestingly, one of the major features of MM is the extreme heterogeneity of median DNA methylation levels, which ranges from globally hypo-to globally hypermethylated as compared to NPCs. This heterogeneity in MM is remarkably higher than in other malignancies of the B-cell lineage (Fig. 1C) . Premalignant MGUS samples were less heterogeneous than MM but shared a similar hypermethylation signature. In contrast, hypomethylation in MM was much more extensive and heterogeneous than in MGUS, suggesting that it may be related to progression from MGUS to MM, as previously reported (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013) . In contrast to other studies (Walker et al. 2011 ), we did not observe the epigenetic variability in MM to be associated with particular genetic changes. However, we cannot rule out the possibility that some genetic features, not analyzed in our study, could be correlated with the heterogeneous DNA methylome. Although the causes of epigenetic heterogeneity in MM require further investigation, we postulate that this phenomenon could be the consequence of both the DNA methylation pattern of the founder plasma cell clone within the heterogeneous plasma cell pool and the proliferative history of the neoplastic cells in a particular case.
One of the most unexpected findings of our study is that DNA hypermethylation in MGUS and MM occurred in regions outside CGIs. This finding contrasts with the classical cancer-associated CIMP (Issa 2004; Fang et al. 2014 ) and recent whole-methylome reports, in which hypermethylation is invariably associated with CGIs and CGI shores close to promoter regions (Berman et al. 2011; Hansen et al. 2011; Kulis et al. 2012 ). Remarkably, a large proportion of hypermethylated CpGs in MM and MGUS were located within intronic regions with enhancer-related chromatin marks in nonmalignant mature B cells and plasma cells. Analyzing the methylation of these regions in the context of Bcell differentiation, we observed a gradual demethylation from stem cells to plasma cells. Hence, the observed methylation pattern of these regions in MM is similar to undifferentiated precursor and stem cells. This finding may reveal new potential insights in the biology of the disease. On the one hand, it may represent a de novo epigenetic reprogramming in MM, leading to the acquisition of a methylation pattern related to stemness. On the other hand, we cannot rule out that the observed pattern could reflect an epigenetic imprint of initial premalignant phases of the disease in progenitor cells.
Our analysis of the chromatin in B cells, plasma cells, and MM revealed that enhancer hypermethylation in MM was associated with enhancer decommissioning, as recently shown in prostate and breast cancer (Taberlay et al. 2014) . Several studies have provided evidence indicating that the binding of specific TFs mediates the loss of DNA methylation at regulatory elements during the cell differentiation (Stadler et al. 2011; Lee et al. 2012; Feldmann et al. 2013; Hon et al. 2013; Kulis et al. 2013) . Here, we have observed that the hypermethylation and decommissioning of specific Bcell enhancers in MM appear to be related to down-regulation of a network of B-cell TFs. Similarly to the globally heterogeneous methylation pattern, this hypermethylation of B-cell enhancers also varied among different cases and may be useful to detect disease subtypes. Interestingly, ∼20% of the MM patients express the B-cell marker CD20 (San Miguel et al. 1991) . We speculate that this MM subtype may lack hypermethylation and decommissioning of B-cell enhancers, allowing part of the B-cell signature to be maintained. In conclusion, our results suggest that MMs show a widely heterogeneous DNA methylation pattern. Embedded into an extensive hypomethylated genome, we identified DNA hypermethylation of developmentally regulated enhancers as a new epigenetic feature of MM. The delineation of the precise role of enhancer hypermethylation in MM pathogenesis and its potential usefulness in the clinical setting as a new source of epigenetic biomarkers should be further investigated.
Methods Patient samples and cell line
Purified plasma cells from bone marrow aspirations were obtained from newly diagnosed patients of MM (n = 104) and MGUS (n = 16). As negative controls, we purified plasma cells from healthy donors (eight tonsils and 12 bone marrows, the latter pooled into three samples of four donors each). The MM cell line U266 was kindly provided by Dr. Cigudosa (Spanish National Cancer Centre-CNIO, Madrid, Spain). Further details on the biological materials used in our study are described in the Supplemental Material.
DNA methylation analysis
Whole-genome bisulfite sequencing and HumanMethylation450 BeadChip (Illumina) were carried out in order to analyze the DNA methylation profile of MM, MGUS, normal plasma cells, and the U266 MM cell line. Details on the experimental procedures, annotation of CpG sites, detection of differentially methylated regions, and Gene Ontology analysis are described in the Supplemental Material.
Analysis of RNA-seq data RNA samples from 11 MMs (also analyzed by Human Methylation450 BeadChip) and four NPCs from tonsils were sequenced using the standard Illumina protocol. Technical details are described in the Supplemental Material.
Luciferase reporter assay pCpGL empty vector and pCpGL-CMV/EF1 were kindly provided by Dr. Rehli (University Hospital, Regensburg, Germany). To properly initiate the transcription, a CpG free minimal promoter (5 ′ -AGAGGGTATATAATGGAAGCTTAACTTCCAG-3´) was also cloned in the pCpGL empty vector (see details in the Supplemental Material).
ChIP-seq and DNase-seq
ChIP-seq was performed in NPCs and in the U266 cell line, and DNase-seq was carried out only on the latter. Standard protocols generated within the Blueprint Consortium were followed. Protocol details can be found at http://www.blueprint-epigenome .eu/index.cfm?p=7BF8A4B6-F4FE-861A-2AD57A08D63D0B58.
Mapped reads of the ChIP-seq data for H3K4me1 and H3K27ac as well as DNase-seq data from the cell lines GM12878 and H1 were downloaded from the UCSC Genome Browser (GRCh37/hg19 Assembly; http://genome-euro.ucsc.edu).
Read density around the 794 CpGs hypermethylated in MM was calculated by seqMINER tool using a 5-kb window upstream and downstream from the CpGs of interest (Ye et al. 2011) .
